Search alternatives:
system decrease » step decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » greater decrease (Expand Search)
via large » a large (Expand Search)
_ system » _ systems (Expand Search), _ systemic (Expand Search)
system decrease » step decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » greater decrease (Expand Search)
via large » a large (Expand Search)
_ system » _ systems (Expand Search), _ systemic (Expand Search)
-
1
-
2
-
3
-
4
Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.
Published 2024“…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”
-
5
-
6
-
7
Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest.
Published 2025“…<p>Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest.…”
-
8
-
9
-
10
-
11
-
12
The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.
Published 2025“…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. (D) As a result, the introduction of mutualistic interactions promotes a growth in complexity in communities where it was once established as low, while stopping the introduction of further mutualistic interactions causes a slight decrease in complexity. …”
-
13
-
14
-
15
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
16
-
17
-
18
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
19
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
20